About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

PET Imaging in ALS Patients | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT02236897

PET Imaging in ALS Patients

This is a pilot study to evaluate a potential imaging biomarker for aiding diagnosis and monitoring progression of ALS, based on a well established basic science pathway, published human autopsy data,...

Lead sponsor: Johns Hopkins University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Johns Hopkins University

Collaborators

ALS Association

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Male or female ALS patients, ranging in age from 18-80.
•Must meet El Escorial Criteria for Probable or Definite ALS.
•Disease duration \>1 year, but \<3 years.
•Weakness in at least two extremities.
•Forced vital capacity less than 80% and greater than 50%.

Exclusion Criteria

•Documented orthopnea or otherwise unable to lie flat in a PET scanner for 90 minutes.
•Presence of pacemakers, aneurysm clips, shrapnel, or other implanted metallic devices that would preclude an MRI scan.
•Absence of sufficient collateral arterial circulation for radial arterial line placement in both wrists.
•Significant abnormalities of hepatic or renal function, or illicit substance use.
•Positive drug screen. (Subjects currently taking prescribed narcotic medication who have a positive drug screen for this medication will not be excluded. Medication history will be obtained during screening).
•Weighs \> 350 lbs.

Related studies

Healing ALS Registry Observational Study (HAROS)

NCT07233148 · Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND), and more

RECRUITINGPhase 1/2

A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

NCT07369076 · Amyotrophic Lateral Sclerosis (ALS)

Retinal Imaging in Neurodegenerative Disease

NCT03233646 · Alzheimer's Disease, Mild Cognitive Impairment, and more

Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.

NCT07187388 · Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), and more

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging

NCT07202494 · Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 7, 2017Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment36

Start dateAug 2013

Last updatedMar 7, 2017

Condition

Amyotrophic Lateral Sclerosis (ALS)

Locations shown

Johns Hopkins University

Baltimore, Maryland

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 7, 2017Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions